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Urinary tract infections are a severe public
health problem and remain one of the most common
community-acquired bacterial infections. Commu-
nity-acquired urinary tract infections affect approxi-
mately 10-20% of the population, while hospital-
acquired urinary tract infections account for approx-
imately 30-40% of all nosocomial infections (1-3).
Urinary tract infections are caused by a wide
range of pathogens, including gram-negative and
gram-positive bacteria and fungi. The predominant
causative agent of both uncomplicated and compli-
cated urinary tract infections is E. coli, especially
uropathogenic strains. Others aetiological agents of
uncomplicated urinary tract infections include gram-
negative rod-shaped bacteria of the Enterobacteria-
ceae, such as Proteus mirabilis, Klebsiella pneumo-
niae, Citrobacter spp., and Enterobacter spp., as well
as gram-positive cocci, such as Staphylococcus
saprophyticus and Enterococcus spp. Complicated
urinary tract infections occur in patients with func-
tional or anatomical obstructions of urine-flow or
host defense dysfunctions and are caused by the
gram-negative bacteria K. pneumoniae, P. mirabilis,
Enterobacter spp., Serratia marcescens, Pseudomo-
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Abstract: Urinary tract infections caused by wide range of pathogens including gram-negative and gram-posi-
tive bacteria as well as fungi are a severe public health problem. The predominant causative agent of both
uncomplicated and complicated urinary tract infections is Escherichia coli. In an era of increasing bacterial
resistance to antimicrobial agents and a high prevalence of multidrug-resistant (MDR) strains in community-
and hospital-acquired infections, the re-evaluation of older generations of antimicrobial agents, such as nitro-
furan derivatives, seems to be a reasonable approach. The aim of the study was to evaluate furazidin activity
against common uropathogens in comparison to nitrofurantoin and other selected antimicrobial agents, rou-
tinely used in the treatment of urinary tract infections. Furazidin exhibited lower MICs than nitrofurantoin when
tested against gram-negative and gram-positive bacteria including clinical MDR E. coli and methicillin-resist-
ant Staphylococcus aureus. The MICs for furazidin ranged from 4 to 64 mg/L for Enterobacteriaceae strains,
from 2 to 4 mg/L for gram-positive cocci, and 0.5 mg/L for anaerobic bacteria. The MICs for nitrofurantoin
ranged from 16 to 64 mg/L for Enterobacteriaceae strains, from 8 to 64 mg/L for gram-positive cocci, and 4
mg/L for anaerobic bacteria. In addition, both nitrofurans displayed better activity against the tested bacterial
strains than ciprofloxacin, fosfomycin, trimethoprim and co-trimoxazole. Nitrofuran derivatives displayed
higher antimicrobial activity than other antimicrobial agents regardless of bacteria species or resistance mech-
anism.
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nas aeruginosa, and Acinetobacter spp., as well as
the gram-positive cocci: Enterococcus spp. and S.
aureus (2-5).
The Infectious Diseases Society of America
(IDSA) and the European Society for Clinical
Microbiology and Infectious Diseases (ESCMID) as
well as polish Recommendations for diagnosis, ther-
apy and prevention of urinary tract infections in
adults edited by Hryniewicz and Holecki in 2015,
recommend nitrofurantoin, fosfomycin, co-trimoxa-
zole, beta-lactams (especially amoxicillin/clavulanic
acid) or fluoroquinolones in treatment of uncompli-
cated urinary tract infections (3, 6).
The main reason for treatment failure in these
infections is the increasing resistance of uropatho-
gens to commonly used antibiotics and chemothera-
peutics. Among strains isolated from nosocomial
and community-acquired infections, extended-spec-
trum beta-lactamases (ESBL) producing Enterobac-
teriaceae are the most frequently isolated. Extended-
spectrum beta-lactamases with substantial potential
to hydrolyse beta-lactam rings are able to hydrolyse
penicillins, cephalosporins (but not cephamycins,
e.g. cefoxitin), and monobactam antibiotics. More-
over, ESBL production is often accompanied by
resistance to fluoroquinolones, co-trimoxazole or
aminoglycosides (3, 4, 7-9). The reason for treat-
ment failures of urinary tract infections caused by
gram-positive bacteria results from resistance to gly-
copeptides of Enterococcus spp. and to methicillin
of staphylococci strains. Resistance to methicillin
reduces the activity of all beta-lactam antibiotics
activity and is often associated with resistance to
macrolides, lincosamides and streptogramins B
(MLSB antibiotics) (10) and a decreased susceptibil-
ity to aminoglycosides and quinolones (3, 4, 11). It
is worth noting that emergence of MDR among
uropathogens, defined as acquired non-susceptibili-
ty to at least one agent in three or more antimicrobial
categories, additionally limits the antibiotics options
(12).
In the era of progressive increases of bacterial
resistance to antimicrobial agents, a re-evaluation of
the efficacy of older generations of antimicrobial
agents, such as nitrofuran derivatives (e.g. nitrofu-
rantoin and furazidin, Fig. 1), may provide addition-
al information on their treatment potential.
The therapeutic efficacy of nitrofuran deriva-
tives is the consequence of their multidirectional
mechanisms of action, which impact various
processes crucial for bacterial cell functions. The
first pathway involves metabolic reduction by nitro-
reductases to form highly reactive intermediates
such as nitrosamine and/or hydroxylamine deriva-
tives, and aromatic amine derivatives. These meta-
bolic intermediates fully inhibit the synthesis of pro-
teins in bacterial cells. The second path consist of
the one-electron reduction of nitro groups to gener-
ate nitroanions, which are responsible for the oxida-
tion of oxygen to superoxide radical anions. The
resulting radicals damage bacterial cells, causing
permanent structural changes to DNA, RNA, and
mitochondria. It thus seems that the extended mech-
anism of action of nitrofuran derivatives might be
responsible for lower drug resistance in comparison
to other antibiotics (13-15).
Nitrofurantoin has recently been the subject of
intensive evaluation towards different pathogens
responsible for urinary tract infections (13, 14).
However, current knowledge of the antimicrobial
activity of furazidin is lacking and there is an insuf-
ficient data on the susceptibility of different bacter-
ial species to furazidin. Thus, the aim of this study
was to evaluate furazidin activity against common
uropathogens (Enterobacteriaceae strains, gram-
positive cocci and anaerobic bacteria) in comparison
to nitrofurantoin and other selected antimicrobial
agents (ciprofloxacin, fosfomycin, trimethoprim and
co-trimoxazole) routinely used in the treatment of
urinary tract infections. We also evaluated the activ-
ity of furazidin against MDR strains of E. coli and S.
aureus and performed a preliminary comparative




The analysis of the activities of selected
antimicrobial agents was performed against a total
Figure 1. Chemical structure of nitrofurantoin (E)-1-[(5-nitro-2-furyl)methylideneamino]imidazolidine-2,4-dione and furazidin (1-{[3-(5-
nitro-2-furyl)prop-2-en-1-ylidene]amino}imidazolidine-2,4-dione)
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of 46 strains, including 34 clinical strains and 12 ref-
erence strains: 10 strains of ATCC collection and
two of other collections (BAA, NCIMB). Among
gram-negative bacteria of Enterobacteriaceae 24
strains were tested: 18 strains clinical ESBL-posi-
tive E. coli and six reference strains, such as: E. coli
ATCC 25922, E. coli ATCC 35218, K. pneumoniae
ATCC 700603, Enterobacter aerogenes NCIMB
10102, P. mirabilis ATCC 12453 and Salmonella
enterica subsp. enterica serovar Agona ATCC
51957. The analysis was also conducted against 20
gram-positive cocci including 16 clinical MRSA
isolates and additionally four reference strains: S.
aureus ATCC 25923, S. aureus BAA 976, S. epider-
midis ATCC 12228, Enterococcus faecalis ATCC
29212. Moreover, anaerobic reference strains:
Bacteroides fragilis ATCC 25285, Prevotella
loescheii ATCC 15930 were included to the study.
Among E. coli strains, five were isolated from
outpatients who suffered urological complications
after invasive procedures (e.g. catheterization) and
13 isolates from patients hospitalized in the inten-
sive care unit. Species identification, susceptibility
testing and determination of ESBL activity via the
double-disc method (16) and via PCR were all per-
formed. In total, seven S. aureus strains were isolat-
ed from subjects of the outpatient clinic, while nine
isolates from patients hospitalized in the intensive
care unit. The identification of species and suscepti-
bility testing of MRSA and MLSB resistant S. aureus
strain were also performed.
PCR based diagnosis of ESBL
Bacterial genomic DNA was isolated with the
use of commercial kit (Genomic Mini, A&A
Biotechnology, Poland) according to the manufac-
turerís instructions. The amplification studies
included three separate reactions, one for each beta-
lactamase encoding gene: blaCTX-M-1, blaSHV and
blaTEM.
The blaCTX-M-1, blaSHV and blaTEM related genes
were respectively amplified by using the following
primer pairs: P1C (TTAATTCGTCTCTTCCAGA)
and P2D (CAGCGCTTTTGCCGTCTAAG) (17),
SHV-A (ACTGAATGAGGCGCTTCC) and SHV-C
(CGCACCCCGCTTGCT), and TEM-A (ATAAAA
TTCTTGAAGAC) and TEM-B (TTACCAAT-
GCTTAATCA) (9). PCR was performed in thermo-
Table 1. Antimicrobial susceptibility testing of clinical Escherichia coli strains against antimicrobials recommended in urinary tract infec-
tions treatment.
No. Strain Origin
Resistance mechanisms Antimicrobial susceptibility testing
Fenotyping Genotyping Ciprofloxacin Fosfomycin Trimethoprim Co-trimoxazole
1 E. coli 1 24950 CA 1 ESBL CTX-M-1 R 3 R R R
2 E. coli 2 25251 CA ESBL CTX-M-1 R R R R
3 E. coli 3 25080 CA ESBL undefined R S R R
4 E. coli 4 27206 CA ESBL CTX-M-1 R S R R
5 E. coli 5 33685 CA ESBL CTX-M-1 S 4 S S S
6 E. coli 12 HA 2 ESBL CTX-M-1 R R S S
7 E. coli 304 HA ESBL CTX-M-1 R S R R
8 E. coli 467 HA ESBL CTX-M-1 R S R R
9 E. coli 540 HA ESBL CTX-M-1 R S R R
10 E. coli 640 HA ESBL CTX-M-1 R S R R
11 E. coli 672 HA ESBL undefined R S S S
12 E. coli 1267 HA ESBL TEM, CTX-M-1 R S R R
13 E. coli 1361 HA ESBL CTX-M-1 R S R R
14 E. coli 1665 HA ESBL CTX-M-1 R S R R
15 E. coli HA ESBL CTX-M-1 R S R R
16 E. coli 2032 HA ESBL CTX-M-1 R S R R
17 E. coli 3086 HA ESBL TEM R S S S
18 E. coli 4191 HA ESBL SHV R S S S
No. (percentage) of resistant strains 17 (94.4%) 3 (16.6%) 13 (72.2%) 13 (72.2%)
1CA - community acquired; 2HA - hospital acquired; 3R - resistant; 4S - susceptible
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cycler T personal (Biometra, Germany). The condi-
tions for the blaCTX-M-1 and blaSHV amplifications
were as follow: initial denaturation at 94OC for 2
min, 30 cycles of 94OC for 30 s, 55OC for 30 s, 72OC
for 45 s and a final elongation at 72OC for 5 min. The
blaTEM PCR amplification conditions were as fol-
lows: 94OC for 3 min, 30 cycles of 94 C for 15 s,
42OC for 30 s, 72OC for 30 s and a final elongation at
72OC for 7 min. All amplicons were subjected to
electrophoresis in a 2% agarose gel and stained with
ethidium bromide.
Antimicrobial susceptibility testing
Antimicrobial susceptibility testing of clinical
isolates against ciprofloxacin, fosfomycin, trimetho-
prim and co-trimoxazole were performed and analysed
according to the EUCAST recommendations (18).
The efficacy of nitrofuran derivatives was
assessed by determining minimal inhibitory concen-
trations using the broth microdilution or agar dilu-
tion method (19). The interpretation of susceptibili-
ty was carried out for nitrofurantoin according to the
EUCAST clinical breakpoints (18). The MIC break-
points for furazidin were not established. Furazidin
is often incorrectly administered to the patients,
based on nitrofurantoin susceptibility (3).
The broth microdilution method was conducted
to obtain MIC values of aerobic bacterial strains. An
inoculum of 1 McFarland in sterile 0.85% NaCl solu-
tion was prepared from a pure bacterial culture
grown for 24 h. The analysis was conducted in a 96-
well microtiter plate. Bacterial inoculums were
aliquoted into the wells with 150 µL of Mueller
Hinton Broth (MHB) (Oxoid, UK) containing the
tested antimicrobial compounds at appropriate dilu-
tions. The concentration of the bacterial cells in each
well was approximately 106 CFU/mL. The positive
control was MHB inoculated with bacterial suspen-
sion. The plates were incubated in an orbital shaker
incubator (150 rpm, 37OC, aerobic atmosphere, 24 h).
Two replicate samples were tested in double repeats
for each condition to ensure repeatability. The results
were analysed in relation to the absorbance of the
positive control. The MIC values were considered to
be the lowest antimicrobial concentration having an
absorbance level = 0.1. The optical densities were
Table 2. Activity of furazidin and nitrofurantoin against clinical Enterobacteriaceae strains obtained by the
broth microdilution method.
No. Strain
MIC [mg/L]   
Furazidin Nitrofurantoin
1 E. coli 124950 16 32
2 E. coli 2 25251 8 32
3 E. coli 3 25080 8 16
4 E. coli 4 27206 4 16
5 E. coli 5 33685 8 16
6 E. coli 12 8 16
7 E. coli 304 8 16
8 E. coli 467 8 16
9 E. coli 540 8 32
10 E. coli 640 8 16
11 E. coli 672 16 32
12 E. coli 1267 64 32
13 E. coli 1361 8 32
14 E. coli 1665 16 32
15 E. coli 1913 8 16 
16 E. coli 2032 8 16
17 E. coli 3086 8 16
18 E. coli 4191 16 32
MIC 50 8 16   
MIC 90 16 32
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measured at 600 nm (OD600) using a spectropho-
tometer (Tecan SunRise, Switzerland).
Agar dilution method were performed for
anaerobic bacterial strains. Cells from pure cultures
(grown for seven days) were resuspended in sterile
0.85% NaCl solution (bioMÈrieux, France) to obtain
an equivalent of 1 McFarland. The inoculum was
spread onto Schaedler Agar (Oxoid, UK) with 5%
sheep blood plates containing appropriate dilutions
of the antimicrobial agents and was incubated in an
anaerobic atmosphere (GenBag anaer, bioMÈrieux,
France) at 37OC for seven days. The MICs were
defined as the lowest dilution that inhibited bacteri-
al growth. All tests were conducted in duplicate.
Kinetic assay of furazidin and nitrofurantoin
activities against S. aureus and E. coli strains
To assess the effect of furazidin and nitrofu-
rantoin on bacterial growth, 18 h assay were per-
formed. In total, 7 concentrations of nitrofuran
derivatives were prepared (0.5 ◊ MIC ñ 16 ◊ MIC)
in MHB with final volumes of 200 µL. Each well
Table 3. Activity of furazidin and nitrofurantoin against reference Enterobacteriaceae strains obtained by the
broth microdilution method.
No. Strain
MIC [mg/L]   
Furazidin Nitrofurantoin
1 E. coli ATCC 25922 8 16   
2 E. coli ATCC 35218 8 16   
3 K. pneumoniae ATCC 700603 32 64   
4 P. mirabilis ATCC 12453 32 64   
5 E. aerogenes NCIMB 10102 32 32   
6 S. enterica ATCC 51957 32 32
Table 4. Antimicrobial susceptibility testing of clinical Staphylococcus aureus strains against antimicrobials recommended in urinary tract
infections treatment.
No. Strain Origin
Resistance Antimicrobial susceptibility testing 
mechanisms Ciprofloxacin Fosfomycin Trimethoprim Co-trimoxazole  
1 S. aureus 8 CA 1 MRSA, MLSB S 4 S S S
2 S. aureus 808 CA MRSA, MLSB R 3 S S S
3 S. aureus 991 CA MRSA, MLSB R S S S
4 S. aureus 2035 CA MRSA, MLSB S S S S
5 S. aureus 2418 CA MRSA, MLSB R S R R
6 S. aureus 4836 CA MRSA, MLSB R S R R
7 S. aureus 6718 CA MRSA, MLSB S S S S
8 S. aureus 212 HA2 MRSA S S S S
9 S. aureus 375 HA MRSA S S S S
10 S. aureus 385 HA MRSA, MLSB R S S S
11 S. aureus 403 HA MRSA, MLSB R S S S
12 S. aureus 466 HA MRSA, MLSB S S S S
13 S. aureus 511 HA MRSA, MLSB R S R S
14 S. aureus 675 HA MRSA S S S S
15 S. aureus 728 HA MRSA, MLSB R S R
16 S. aureus 2110 HA MRSA, MLSB R S S S
No. (percentage) of resistant strains 9 (56.3%) 0 (0%) 4 (25%) 3 (18.8%)
1CA ñ community acquired; 2HA ñ hospital acquired; 3R ñ resistant; 4S ñ susceptible
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was inoculated with bacterial suspension to obtain a
concentration of approximately 106 CFU/mL. The
optical density was measured at 600 nm in 2 h inter-
vals for 18 h.
RESULTS
The selected nitrofuran derivatives furazidin
and nitrofurantoin were evaluated in vitro for their
antimicrobial activity against resistant and suscepti-
ble strains of Enterobacteriaceae, gram-positive
cocci and anaerobic bacteria. In addition, the sus-
ceptibility to ciprofloxacin, fosfomycin, trimetho-
prim and co-trimoxazole of clinical E. coli and S.
aureus strains were assessed.
Activities of furazidin and nitrofurantoin against
Enterobacteriaceae strains
Furazidin and nitrofurantoin were tested for
their antimicrobial activities against 24 Enterobac-
teriaceae strains. 
Clinical strains
All 18 clinical E. coli strains were identified as
ESBL-positive according to the phenotypic double-
disc synergy test as well as beta-lactamase produc-
tion were confirmed by PCR. The molecular studies
concerning the presence of selected ESBL encoding
genes revealed that 14 E. coli strains carried the
genes belonging to the blaCTX-M-1 group, one to the
blaTEM and one to the blaSHV. Within the analysed
strains the co-existence of blaCTX-M-1 and blaTEM was
observed in one isolate while two strains possessed
undefined ESBL genotypes. Among analysed
strains, the resistance rate amount to 94.4% for
ciprofloxacin, 72.2% for trimethoprim, 72.2% for
co-trimoxazole and 16.6% for fosfomycin (Table 1).
In contrary, all 18 tested E. coli strains remained
within the susceptibility criteria for nitrofurantoin,
according to the EUCAST clinical breakpoints.
Nitrofuran derivatives displayed higher activi-
ties against MDR E. coli strains than other tested
antimicrobial agents. The MIC values for furazidin
obtained by the broth microdilution method for clin-
ical E. coli strains ranged from 4 mg/L to 64 mg/L
(MIC50 amounted to 8 mg/L and MIC90 ñ 16 mg/L)
while the MICs for nitrofurantoin ranged from 16
mg/L to 32 mg/L (MIC50 amounted to 16 mg/L and
MIC90 ñ 32 mg/L). The comparison of MIC50 and
MIC90 values showed better activity of furazidin
Table 5. Activity of furazidin and nitrofurantoin against tested clinical gram-positive strains obtained by the
broth microdilution method.
No. Strain
MIC [mg/L]   
Furazidin Nitrofurantoin
1 S. aureus 8 4 16
2 S. aureus 808 4 16
3 S. aureus 991 4 16
4 S. aureus 2035 4 16
5 S. aureus 2418 4 16
6 S. aureus 4836 2 8
7 S. aureus 6718 4 16
8 S. aureus 212 4 16 
9 S. aureus 375 4 16 
10 S. aureus 385 4 32
11 S. aureus 403 4 32
12 S. aureus 466 4 16
13 S. aureus 511 4 16
14 S. aureus 675 4 16
15 S. aureus 728 4 16
16 S. aureus 2110 4 16
MIC 50 4 16
MIC 90 4 16
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than nitrofurantoin against MDR E. coli isolates
(Table 2). 
Reference strains
Moreover, the nitrofuran derivatives were
evaluated against six Enterobacteriaceae strains
belonging to ATCC and NCIMB collections. The
MIC values for furazidin obtained by the broth
microdilution method for reference gram-negative
strains ranged from 8 mg/L to 32 mg/L while the
MICs for nitrofurantoin ranged from 16 mg/L to 64
mg/L. Furazidin and nitrofurantoin exhibited similar
activities against E. aerogenes NCIMB 10102 strain.
It is worth noting, that furazidin showed 2-fold high-
er activity than nitrofurantoin against P. mirabilis,
which remains naturally resistant to nitrofurantoin
(20). Similarly, 2-fold lower MIC for furazidin than
nitrofurantoin for E. coli and K. pneumoniae was
observed (Table 3).
Activities of furazidin and nitrofurantoin against
strains of gram-positive bacteria
Clinical strains
Among 16 tested MRSA strains, 13 presented
co-existence with the MLSB resistance mechanisms
(Table 4). Moreover, 56.3% of strains were resistant
to ciprofloxacin, 25% to trimethoprim and 18.8% to
co-trimoxazole (Table 4).
Among evaluated nitrofuran derivatives
furazidin displayed higher activity against gram-
positive cocci than nitrofurantoin. MIC values
obtained for furazidin using the broth microdilution
method ranged from 2 to 4 mg/L (MIC50 and MIC90
amounted to 4 mg/L), while MIC values for nitrofu-
rantoin ranged from 8 to 32 mg/L (MIC50 and MIC90
amounted to 16 mg/L) (Table 5). The comparison of
MIC50 and MIC90 values showed better activity of
furazidin than nitrofurantoin against MDR S. aureus
isolates. 
Reference strains
MIC values obtained for furazidin for refer-
ence gram-positive strains ranged from 2 to 4 mg/L,
while MIC values for nitrofurantoin ranged from 16
to 64 mg/L. Furazidin showed higher antibacterial
activity than nitrofurantoin against S. aureus BAA
976, S. aureus ATCC 25923, S. epidermidis ATCC
12228 and E. faecalis ATCC 29212 (Table 6).
Activities of furazidin and nitrofurantoin against
reference strains of anaerobic bacteria
Both nitrofuran derivatives furazidin and nitro-
furantoin had low MIC values against anaerobic
bacteria strains. However, furazidin displayed lower
MIC values than nitrofurantoin (0.5 mg/L vs 4
mg/L) (Table 7).
Preliminary kinetic assay of furazidin and nitro-
furantoin activities against S. aureus and E. coli
strains
Analyses of antibiotic or chemotherapeutic
MICs were based on the OD600 values with the cut-off
point set at an OD600 value of 0.1. The graphs show the
changing density of the bacterial culture during expo-
sure to different drug concentrations. Representative
curves for E. coli 4 and MRSA 511 show bacterial
Table 6. Activity of furazidin and nitrofurantoin against selected reference gram-positive strains obtained by
the broth microdilution method.
No. Strain
MIC [mg/L]   
Furazidin Nitrofurantoin
1 S. aureus BAA 976 4 16
2 S. aureus ATCC 25923 4 64
3 S. epidermidis ATCC 12228 2 32
4 E. faecalis ATCC 29212 4 32 
Table 7. MIC values of furazidin and nitrofurantoin against reference strains of anaerobic bacteria obtained by




B. fragilis ATCC 25285 0.5 4
P. loescheii ATCC 15930 0.5 4
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growth in the presence of increasing concentrations of
furazidin and nitrofurantoin. The maximal bacterial
density (maximum OD600 value) of drug-free control
occurred after 8 h of incubation (Fig. 2).
DISCUSSION AND CONCLUSION
Antimicrobial resistance among bacteria isolat-
ed from community-acquired or nosocomial urinary
tract infection has been steadily increasing, especial-
ly for beta-lactams, co-trimoxazole and fluoro-
quinolones (6, 14). At the same time a diminishing
number of approvals for new antimicrobials active
against uropathogens has been observed (14). Thus,
in the era of increasing bacterial resistance, the re-
evaluation of nitrofurans is a potential way to obtain
drugs for the successful therapy of urinary tract infec-
tions caused by strains resistant to other commonly
used drugs, especially by MDR bacterial strains.
In the USA, an alarming problem exists where
a high prevalence of outpatient MDR E. coli strains,
which has markedly grown from 9.1% in 2001 to
17% in 2010 (21). According to the surveillance
study carried out in Europe and Brazil between 2006
and 2008 of the antimicrobial resistance of
pathogens from uncomplicated urinary tract infec-
tions, 48.2% of E. coli strains were resistant to ampi-
cillin, 29.4% to co-trimoxazole and 8.1% to
ciprofloxacin (22). In Poland, between 2006 and
2008, the resistance rate of E. coli isolated from
uncomplicated cases of urinary tract infections was
40% for ampicillin, 20% for co-trimoxazole and
6.7% for ciprofloxacin. Among isolates from noso-
comial urinary tract infections, resistance to antimi-
crobial agents was higher, with 56.8% of strains
being resistant to ampicillin, 35% to tetracycline,
23.1% to co-trimoxazole to 19.4% to ciprofloxacin
(3, 22, 23). The prevalence of resistance to nitrofu-
rantoin among E. coli strains is relatively low com-
pared to other antimicrobial agents, with only 2% of
isolates in Europe and USA showing resistance. In
Poland, 4.4% of E. coli strains isolated from com-
munity-acquired urinary tract infections were resist-
ant to nitrofurantoin, as well as 3.75% of isolates
from nosocomial infections (3, 22-24).
Despite the increasing bacterial resistance to
antimicrobial agents, nitrofurantoin  remains a good
option in the treatment of community-acquired uri-
nary tract infections caused by E. coli. Nitro-
furantoin has maintained good antimicrobial activi-
ty despite its extensive clinical use worldwide for
over 50 years, and it still possesses good bacterici-
dal activity against MDR E. coli (7, 13-15, 21, 24-
26) as well as vancomycin-resistant enterococci
strains (11, 13, 15).
The main purpose of this study was to re-inves-
tigate the antimicrobial activities of selected nitrofu-
ran derivatives against common uropathogens. Our
Figure 2. Representative growth curves of clinical MDR strains: Escherichia coli 4 and MRSA 511 at different concentrations of furazidin
and nitrofurantoin
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study involved the evaluation of furazidin and nitro-
furantoin against 46 strains: 34 clinical MDR strains
of E. coli and S. aureus and 12 reference strains: 10
strains of ATCC collection and two of other collec-
tions (BAA, NCIMB). Generally, evaluated nitrofu-
ran derivatives displayed higher antimicrobial activ-
ity in comparison to the other tested antimicrobial
agents (ciprofloxacin, trimethoprim and co-trimoxa-
zole) regardless of the species of bacteria or their
resistance mechanism. It was shown that nitrofuran
derivatives retained their activity against all clinical
MDR strains of E. coli and S. aureus. Among other
tested antimicrobials, fosfomycin demonstrated
good antimicrobial activity and was active against
all S. aureus strains and against 83.4% of E. coli
strains (Table 1, Table 4).
While much research has been focused on
activity of nitrofurantoin against MDR urinary E.
coli isolates, furazidin might be regarded as a valu-
able alternative. Comparative analyses of antibacter-
ial properties revealed higher activity of furazidin in
comparison to nitrofurantoin, expressed as lower
MIC values. Our results are still consistent with pre-
vious outcomes and confirmed lower MIC values
for furazidin than nitrofurantoin (27). The compari-
son of MIC values for furazidin and nitrofurantoin
for all strains showed that only one strain, ESBL-
positive E. coli 1267, expressed a higher MIC value
for furazidin than nitrofurantoin (64 vs 32 mg/L). It
is worth noting that this strain remained susceptible
for nitrofurans according to the EUCAST interpreta-
tion criteria. Moreover, furazidin displayed higher
antimicrobial activity against P. mirabilis and K.
pneumoniae in comparison to nitrofurantoin.
Nitrofuran derivatives expressed good antibac-
terial activity against MDR S. aureus strains. While
S. aureus is unfrequently isolated from community-
acquired urinary tract infections, among hospital-
ized patients is more common (3, 28). MDR S.
aureus is predominantly recovered from long-term
hospitalized patients with urinary tract catheteriza-
tion. Moreover, it is hypothesized that S. aureus uri-
nary tract infection may lead to invasive infection or
staphylococcal bacteraemia (28). Our research
revealed better activity of furazidin than nitrofuran-
toin against MDR S. aureus expressed by 4-fold
lower MIC50 and MIC90 of furazidin than nitrofuran-
toin (4 mg/L vs 16 mg/L, respectively).
Moreover, Zhanel et al. reported nitrofurantoin
to be a good therapeutic option in the treatment of
vancomycin-resistant enterococci isolated from uri-
nary tract infection (11). Our study revealed high
activity of nitrofuran derivatives especially,
furazidin against enterococci (Table 6).
In summary, the increase in bacterial resistance
to antibiotics and chemotherapeutics used in the treat-
ment of urinary tract infections is encouraging initia-
tives to re-investigate the antimicrobial activity of
older generation of drugs. Herein evaluated furazidin
and nitrofurantoin showed higher antimicrobial acti-
vity than ciprofloxacin, trimethoprim and co-trimoxa-
zole regardless of the species of bacteria or the resist-
ance mechanism being tested. Our results suggest that
ciprofloxacin, trimethoprim and co-trimoxazole
should be carefully used in the therapy of urinary tract
infections, regard to the results of antimicrobial sus-
ceptibility testing. Moreover, nitrofuran derivatives
displaying higher antimicrobial activity in compari-
son to other antimicrobials, might be considered as a
good first line therapy of urinary tract infections
against a broad-spectrum of uropathogens, including
MDR strains of E. coli and S. aureus.
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